Holen Sie sich die Stockscreener-App
743.58
0.85%
5.75
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$737.83
Offen:
$736.315
24-Stunden-Volumen:
1.19M
Relative Volume:
0.28
Marktkapitalisierung:
$703.71B
Einnahmen:
$53.26B
Nettoeinkommen (Verlust:
$13.80B
KGV:
48.60
EPS:
15.3
Netto-Cashflow:
$-50.20M
1W Leistung:
+1.66%
1M Leistung:
-3.24%
6M Leistung:
-18.32%
1J Leistung:
-21.37%
1-Tages-Spanne:
$735.33
$745.52
1-Wochen-Bereich:
$723.64
$745.52
52-Wochen-Spanne:
$623.78
$943.00
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
743.52 | 659.07B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
177.95 | 428.83B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
211.74 | 374.37B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
128.63 | 245.16B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
83.19 | 213.51B | 63.43B | 16.42B | 14.72B | 6.49 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Hims & Hers gains after court rejects Eli Lilly’s case against Willow - Yahoo Finance
BMO Capital Markets Reaffirms ‘Buy Rating’ on Eli Lilly Stock (LLY) - TipRanks
Gastric Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Eli Lilly and Company, BeiGene, Hutchison MediPharma, Astellas Pharma, Henlix - Barchart.com
PRESSR: Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity - TradingView
Is Novo Nordisk Stock a Buy Now? - The Motley Fool
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
Fueled by Lilly's Lebanon investment, local builds future in biotech at Ivy Tech - reporter.net
Analyst Forecasts $25 Billion of Annual Sales for Eli Lilly’s (LLY) New Weight-Loss Pill - TipRanks
Eli Lilly's once-daily obesity pill passes phase 3 trials - 조선일보
BMO Capital Affirms Eli Lilly (LLY)’s ‘Outperform’ Rating on Weight Loss Drug Prospects - Yahoo Finance
Eli Lilly's New Drugs Beyond Mounjaro And Zepbound Boost Sales - Barchart.com
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales - Nasdaq
What's Going On With Novo Nordisk Stock Tuesday?Novo Nordisk (NYSE:NVO), Eli Lilly (NYSE:LLY) - Benzinga
Eyes on Asia: Lilly, Fosun, RemeGene - BioXconomy
Lilly Ends Two Mid-Stage Trials for Second Obesity Asset - BioSpace
Is Eli Lilly and Company’s growth already priced inJuly 2025 Decliners & Fast Moving Stock Watchlists - خودرو بانک
Eli Lilly & Co: Strong Buy Rating Driven by Promising Weight Loss Drug and Innovative Subscription Model - TipRanks
Recently, Eli Lilly's obesity treatment "Munzaro" has been released in Korea and interest in obesity.. - 매일경제
Recently, Eli Lilly's obesity treatment Maunzaro was released in Korea, and as interest in obesity t.. - 매일경제
Eli Lilly and Company (LLY) Halts UK Mounjaro Shipments Ahead of Planned Price Increase - uk.finance.yahoo.com
Can trapped investors hope for a rebound in Eli Lilly and CompanyTrade Performance Summary & Detailed Earnings Play Alerts - Newser
Eli Lilly’s SWOT analysis: stock’s growth potential in obesity market faces challenges - Investing.com
Eli Lilly (LLY) Partners with JD.com to Sell Weight-Loss Drugs in China - TipRanks
ESC25: Novo's Wegovy slashes CV risk by 57% over Lilly's Zepbound in real-world study - FirstWord Pharma
Novo Nordisk Says Wegovy Cuts Heart Risk by 57% Compared With Eli Lilly’s Obesity Drug - The Wall Street Journal
Eli Lilly and Company Stock (LLY) Opinions on Orforglipron Trial Data | LLY Stock News - Quiver Quantitative
Can you recover from losses in Eli Lilly and CompanyJuly 2025 Levels & Verified Chart Pattern Trade Signals - Newser
HSBC Upgrades Eli Lilly (LLY) to Hold, Lifts Price Target to $700 - Yahoo Finance
Intraday pattern recognizer results for Eli Lilly and CompanyPortfolio Risk Report & Fast Exit Strategy with Risk Control - Newser
Benzinga Bulls And Bears: Eli Lilly, Firefly, Marvell — And Trump Investment Hints Boost Defense Stocks - inkl
Eli Lilly is close to launching the strongest weight-loss drug ever. Somehow, gym bros are already taking it to shred fat. - Business Insider
Eli Lilly and Company (LLY): A Bull Case Theory - MSN
Sector ETF performance correlation with Eli Lilly and Company2025 Geopolitical Influence & Consistent Profit Trading Strategies - Newser
Eli Lilly and Company (LLY) Needs To Get A Weight Loss Pill Out, Says Jim Cramer - Yahoo Finance
Pharmaceutical Cos. Back Lilly In Mich. Insulin Pricing Probe - Law360
Jim Cramer Sees Big Potential in Eli Lilly’s Weight-Loss and Diabetes Pill - Yahoo Finance
The Zacks Analyst Blog Highlights Lilly, Oracle, Procter & Gamble and Comstock Holding Companies - ca.finance.yahoo.com
Eli Lilly (NYSE:LLY) vs Novo Nordisk (NYSE:NVO): Growth Premium vs Value Upside - tradingnews.com
Eli Lilly (NYSE:LLY) Stock Price Trading at $732 as GLP-1 Sales Surge and Drug Pricing Risks Rise - tradingnews.com
Is Eli Lilly Stock A Buy As The Company Aims For Weight-Loss Pill Approval? - Investor's Business Daily
Eli Lilly Stock: Is LLY Underperforming the Healthcare Sector? - Yahoo Finance
Eli Lilly Temporarily Stops U.K. Shipments of Its Weight-Loss Drug - TipRanks
Eli Lilly Partners with JD Health for Direct-to-Consumer Obesity and Diabetes Drug Sales - AInvest
JD Health (06618.HK) has reached a strategic cooperation agreement with Eli Lilly and Co in China. - 富途牛牛
LLY Stock Quote Price and Forecast - CNN
Eli Lilly Partners With China Tech Giant for Obesity Drug Sales - Bloomberg
Eli Lilly to offer UK discount on Mounjaro weight-loss jabs - The Independent
Decoding Insider Activity at Eli Lilly: A Closer Look at Recent Share Sales and Buying Conviction - AInvest
Top Stock Reports for Eli Lilly, Oracle & Procter & Gamble - Nasdaq
Eli Lilly CIO Susan Ridlen retiring - Pensions & Investments
Eli Lilly (LLY) technical analysisEli Lilly (NYSE:LLY) - Benzinga
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.08%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):